Cohn, D. L., Fisher, E. J., Peng, G. T., Hodges, J. S., Chesnut, J., Child, C. C., Franchino, B., Gibert, C. L., El Sadr, W., Hafner, R., Korvick, J., Ropka, M., Heifets, L., Clotfelter, J., Munroe, D., & Horsburgh, C. R. (1999). A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. International Journal of Leprosy and Other Mycobacterial Diseases, 67(4 SUPPL.), 520-521.
A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. / Cohn, D. L.; Fisher, E. J.; Peng, G. T. et al.
In:
International Journal of Leprosy and Other Mycobacterial Diseases, Vol. 67, No. 4 SUPPL., 1999, p. 520-521.
Research output: Contribution to journal › Article › peer-review
Cohn, DL, Fisher, EJ, Peng, GT, Hodges, JS, Chesnut, J, Child, CC, Franchino, B, Gibert, CL, El Sadr, W, Hafner, R, Korvick, J, Ropka, M, Heifets, L, Clotfelter, J, Munroe, D & Horsburgh, CR 1999, 'A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin', International Journal of Leprosy and Other Mycobacterial Diseases, vol. 67, no. 4 SUPPL., pp. 520-521.
Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. International Journal of Leprosy and Other Mycobacterial Diseases. 1999;67(4 SUPPL.):520-521.
Cohn, D. L. ; Fisher, E. J. ; Peng, G. T. et al. / A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients : Excess mortality associated with high-dose clarithromycin. In: International Journal of Leprosy and Other Mycobacterial Diseases. 1999 ; Vol. 67, No. 4 SUPPL. pp. 520-521.
@article{362fedde8e494e72a87e246468923c56,
title = "A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin",
abstract = "The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 30 patients receiving clarithromycin at 1000 mg b.i.d. (158 deaths per 100 person-years) (relative risk 2.43; 95% confidence interval 1.11-5.34; p = 0.02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk 1.20; 95% confidence interval 0.65-2.19; p = 0.56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.",
author = "Cohn, {D. L.} and Fisher, {E. J.} and Peng, {G. T.} and Hodges, {J. S.} and J. Chesnut and Child, {C. C.} and B. Franchino and Gibert, {C. L.} and {El Sadr}, W. and R. Hafner and J. Korvick and M. Ropka and L. Heifets and J. Clotfelter and D. Munroe and Horsburgh, {C. R.}",
year = "1999",
language = "English",
volume = "67",
pages = "520--521",
journal = "International Journal of Leprosy and Other Mycobacterial Diseases",
issn = "0148-916X",
publisher = "Allen Press Inc.",
number = "4 SUPPL.",
}
TY - JOUR
T1 - A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients
T2 - Excess mortality associated with high-dose clarithromycin
AU - Cohn, D. L.
AU - Fisher, E. J.
AU - Peng, G. T.
AU - Hodges, J. S.
AU - Chesnut, J.
AU - Child, C. C.
AU - Franchino, B.
AU - Gibert, C. L.
AU - El Sadr, W.
AU - Hafner, R.
AU - Korvick, J.
AU - Ropka, M.
AU - Heifets, L.
AU - Clotfelter, J.
AU - Munroe, D.
AU - Horsburgh, C. R.
PY - 1999
Y1 - 1999
N2 - The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 30 patients receiving clarithromycin at 1000 mg b.i.d. (158 deaths per 100 person-years) (relative risk 2.43; 95% confidence interval 1.11-5.34; p = 0.02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk 1.20; 95% confidence interval 0.65-2.19; p = 0.56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.
AB - The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 30 patients receiving clarithromycin at 1000 mg b.i.d. (158 deaths per 100 person-years) (relative risk 2.43; 95% confidence interval 1.11-5.34; p = 0.02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk 1.20; 95% confidence interval 0.65-2.19; p = 0.56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.
UR - http://www.scopus.com/inward/record.url?scp=33748250462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748250462&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33748250462
SN - 0148-916X
VL - 67
SP - 520
EP - 521
JO - International Journal of Leprosy and Other Mycobacterial Diseases
JF - International Journal of Leprosy and Other Mycobacterial Diseases
IS - 4 SUPPL.
ER -
